Blueprint Medicines Surges to Ninth Most Traded Stock as Sanofi Agrees to $9.5 Billion Acquisition

On June 2, 2025, Blueprint Medicines Corporation (BPMC) experienced a significant surge in trading volume, with a turnover of 59.26 billion, marking a 6347.29% increase from the previous day. This substantial rise in trading activity positioned Blueprint as the ninth most traded stock of the day, reflecting a notable shift in investor sentiment towards the company.

Sanofi, a prominent French pharmaceutical company, has agreed to acquire Blueprint Medicines Corporation for up to $9.5 billion. This strategic move aims to bolster Sanofi's position in the field of rare immunology diseases. The acquisition includes Blueprint's portfolio of medicines and a promising pipeline in immunology, particularly focusing on systemic mastocytosis (SM), a rare immunological disease.

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Additionally, Blueprint shareholders will receive one non-tradeable contingent value right (CVR) per share, which could entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis.

Sanofi's acquisition of Blueprint is expected to enhance its growing immunology pipeline, particularly with the inclusion of Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis. This medicine has shown significant year-on-year growth, with net revenues of $479 million in 2024 and nearly $150 million in Q1 2025. The acquisition also brings elenestinib, a next-generation KIT D816V inhibitor, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor, both of which have the potential to treat a broad range of diseases in immunology.